Annette von Delft

University of Oxford — United Kingdom

Medicine · Health Sciences

15h-index1.2kcitations32works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatitis C virus research(11), vaccines and immunoinformatics approaches(11), HIV Research and Treatment(7), Monoclonal and Polyclonal Antibodies Research(7), SARS-CoV-2 and COVID-19 Research(5)

Publications31 total

Combined crystallographic fragment screening and deep mutational scanning enable discovery of Zika virus NS2B-NS3 protease inhibitors
Nature Communications·2025· 5 citedOpen Access
Discovery of orally bioavailable Zika and West Nile Virus antiviral compounds targeting the NS2B-NS3 protease
2025· 2 citedOpen Access
Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitor
2025· 3 citedOpen Access
Assessment of repurposed compounds against coronaviruses highlights the antiviral broad-spectrum activity of host-targeting iminosugars and confirms the activity of potent directly acting antivirals
Antiviral Research·2025· 3 citedOpen Access
Identification and characterization of human <i>KALRN</i> mRNA and Kalirin protein isoforms
Cerebral Cortex·2024· 1 citedOpen Access
Assessment of Repurposed Compounds Against Coronaviruses Highlights the Antiviral Broad-Spectrum Activity of Host-Targeting Iminosugars and Confirms the Activity of Potent Directly Acting Antivirals
SSRN Electronic Journal·2024Open Access
An Update on SARS-CoV-2 Clinical Trial Results—What We Can Learn for the Next Pandemic
International Journal of Molecular Sciences·2023· 8 citedOpen Access
Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors
Science·2023· 159 citedOpen Access
Accelerating antiviral drug discovery: lessons from COVID-19
Nature Reviews Drug Discovery·2023· 168 citedOpen Access
Turning high-throughput structural biology into predictive inhibitor design
Proceedings of the National Academy of Sciences·2023· 22 citedOpen Access
Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP)
BMC Musculoskeletal Disorders·2022· 12 citedOpen Access
Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia
CNS Drugs·2021· 11 cited
A white-knuckle ride of open COVID drug discovery
Nature·2021· 44 citedOpen Access
Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses
Cell Reports·2021· 4 citedOpen Access
Open Science Discovery of Potent Non-Covalent SARS-CoV-2 Main Protease Inhibitors
2020· 70 citedOpen Access
MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans
Science Translational Medicine·2020· 32 citedOpen Access
Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes
Vaccine·2020· 13 cited
Incoming HIV Virion-Derived Gag Spacer Peptide 2 (p1) is a Target of Effective CD8+ T Cell Antiviral Responses
SSRN Electronic Journal·2020· 2 citedOpen Access
GS-05-MHC-II invariant chain adjuvanted chimpanzee adenoviral and MVA hepatitis C vaccines elicit unprecedented levels of anti-viral T-cell immune responses in humans
Journal of Hepatology·2019· 2 cited
A pan-genotype HCV T cell vaccine, in a simian adenovirus vector, to target T cell epitopes conserved across multiple HCV genotypes
Journal of Hepatology·2018
page 1 of 2Next →

Frequent Co-authors

Eleanor Barnes(13), Paul Klenerman(12), Alpha A. Lee(9), F. von Delft(8), Anthony Brown(8), D. Fearon(7), Nir London(7), John D. Chodera(6), Haim Barr(6), Lucy Dorrell(6), L. Koekemoer(5), Matthew C. Robinson(5), Juliane Brun(5), Michelle L. Hill(5), Leo Swadling(5), Timothy Donnison(5), Dominic S. Alonzi(4), C. Gileadi(4), J. L. Kiappes(4), Stefania Capone(4)